期刊
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
卷 19, 期 11, 页码 1199-1203出版社
WILEY-BLACKWELL
DOI: 10.1002/pds.2015
关键词
asthma medication use; childhood; inhaled corticosteroids; parental reporting; validity
资金
- GlaxoSmithKline (GSK)
- Astra-Zeneca (AZ)
- Nycomed
- Aerocrine
- Roche
- Friesland Nutrition
- MerckSharpDohme
- Netherlands Organization for Scientific Research (NWO)
- Dutch Asthma Fonds
- ZON-MW Netherlands Organization for Health Research and Development
- Stichting Astmabestrijding
- Ministry of the Environment
Purpose This study was conducted to assess the validity of parental reported use of inhaled corticosteroids (ICS) in children. Methods ICS users were identified within the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study and the PIAMA pharmacy sub-cohort which is nested within the PIAMA study. Complete medication histories were available for the first 8 years of life for children within the PIAMA pharmacy sub-cohort. Parental reported ICS use was measured by using data from questionnaires. ICS use in the pharmacy records was determined by using the Anatomical Therapeutic Chemical (ATC) codes. The proportion of overall agreement and kappa statistics with their corresponding 95% confidence intervals were calculated to quantify agreement between self-reported medication use and pharmacy prescription data. Results At all ages overall agreement was very high (>97%) and Cohen's kappa's ranged from 0.80 to 0.88 which also reflects excellent agreement between parental reported use of ICS and pharmacy prescription data. Conclusions Our finding suggests that parental report of medication use is a reliable source of data to asses ICS use in children. The questionnaire-based medication data collected within the PIAMA study can be used to study asthma medication use in a large group of children. Copyright (C) 2010 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据